Which are the causes of Paroxysmal nocturnal hemoglobinuria?

Paroxysmal nocturnal hemoglobinuria (PNH) is caused by a somatic mutation in the PIGA gene within hematopoietic stem cells, which leads to the production of blood cells lacking essential protective proteins on their surface. This deficiency makes these cells vulnerable to premature destruction by the body's own complement system, resulting in the characteristic symptoms of this rare blood disorder.

What exactly happens at the genetic level in PNH?

To understand Paroxysmal nocturnal hemoglobinuria, it is helpful to look at the "instruction manual" for your blood cells. The disease is caused by an acquired mutation in the PIGA gene, located on the X chromosome. This mutation occurs after birth in a single blood-forming stem cell in the bone marrow. Because this is a somatic mutation—meaning it is not inherited from your parents—it only affects the descendants of that specific mutated cell. The PIGA gene is responsible for creating an anchor (called GPI) that holds various protective proteins onto the surface of blood cells. Without this anchor, blood cells are left "unprotected," acting like a house without a security system.

How does the immune system trigger Paroxysmal nocturnal hemoglobinuria?

In a healthy body, the complement system—a part of the immune system that helps fight infections—is kept in check by regulatory proteins anchored to cells. In Paroxysmal nocturnal hemoglobinuria, because the blood cells lack these protective anchors, the complement system mistakenly identifies them as foreign invaders. This leads to the destruction of red blood cells, a process known as hemolysis. This is not an autoimmune disease in the traditional sense, but rather a failure of the body to distinguish its own "unprotected" cells from harmful pathogens.

Are there environmental or external risk factors?

While the root cause of Paroxysmal nocturnal hemoglobinuria is a genetic mutation, researchers believe there is often a "trigger" that allows the mutated stem cell to outcompete healthy cells. Many patients with Paroxysmal nocturnal hemoglobinuria also have a history of aplastic anemia, a condition where the bone marrow stops producing enough blood cells. Current theories suggest that the immune system may attack healthy stem cells, creating a "niche" or empty space in the bone marrow that allows the mutated, PIGA-deficient cells to proliferate and take over.

What are the key mechanisms of the disease?

The progression of Paroxysmal nocturnal hemoglobinuria involves several distinct biological failures:

• Intravascular Hemolysis: The destruction of red blood cells within the blood vessels, releasing hemoglobin into the plasma.


• Complement Activation: Uncontrolled activity of the terminal complement pathway, which creates "holes" in the cell membrane.


• Thrombosis: A high risk of blood clots, which is the leading cause of mortality in Paroxysmal nocturnal hemoglobinuria, likely due to the activation of platelets and the depletion of nitric oxide.


• Bone Marrow Failure: The underlying inability of the marrow to produce sufficient healthy blood cells.

Is the cause of Paroxysmal nocturnal hemoglobinuria fully understood?

While the PIGA mutation is the well-established "smoking gun," research is ongoing to understand why certain individuals develop clinical symptoms while others may harbor small populations of PNH cells without significant disease. Scientists are currently investigating the interplay between the immune system and the bone marrow microenvironment to better understand why the disease manifests differently across the 162 members of the DiseaseMaps.org community and patients worldwide. Understanding these pathways is critical to developing more targeted, long-term therapies.

Next steps

• Consult a hematologist who specializes in bone marrow failure syndromes or complement-mediated disorders.


• Request a high-sensitivity flow cytometry test to accurately quantify the size of your PNH clone.


• Connect with the DiseaseMaps.org community to share experiences and find support from others living with the condition.


• Discuss current clinical trials for complement inhibitors with your medical team to stay informed on emerging treatments.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• Orphanet: Paroxysmal nocturnal hemoglobinuria (ORPHA:397)


• NIH Genetic and Rare Diseases Information Center (GARD): PNH Overview


• OMIM (Online Mendelian Inheritance in Man): PIGA Gene (#311770)


• Aplastic Anemia and MDS International Foundation (AAMDSIF): Understanding PNH